BRTX

BioRestorative is a pre-commercial cell-therapy developer whose entire value rests on BRTX-100, a Phase 2 candidate for degenerative disc disease that has not been approved or shown to work. The auditor's report and Item 1A both state there is 'substantial doubt about our ability to continue as a going concern within the next twelve months' — that language, not the stock chart, is the governing fact here. The financials corroborate it: FY2025 revenue was just $360K (down 10.3% YoY) against a $14.2M net loss and $10.8M of operating cash burn. Gross margin optically looks great at 93.4%, but on $360K of sales that is meaningless — operating margin is -4,350% because R&D ($10.1M, up 50.5%) and public-company overhead dwarf any product revenue.

The balance sheet is effectively exhausted. Stockholders' equity collapsed 95.8% to $357K, total assets fell 66.8% to $4.08M, and current liabilities ($3.72M) already exceed current assets ($3.14M) — negative working capital with only $1.51M of cash against ~$11M annual burn. That is roughly a single quarter of runway, which is precisely why management is leaning on the Rodman & Renshaw ATM (965,424 shares sold in FY2025) to survive. The consequence shows in the share count: shares outstanding jumped 239.5% YoY to 25.5M, and the accumulated deficit is $170M against a $10.2M market cap. Shareholders are being diluted continuously just to fund another few months of trials.